Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Autor: Edwards ME; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and., Chebib FT; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and., Irazabal MV; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and., Ofstie TG; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and., Bungum LA; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and., Metzger AJ; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and., Senum SR; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and., Hogan MC; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and., El-Zoghby ZM; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and., Kline TL; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and., Harris PC; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and., Czerwiec FS; Otsuka Pharmaceutical Development and Commercialization, Rockville, Maryland., Torres VE; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and.

Publikováno v: Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2018 Aug 07; Vol. 13 (8), pp. 1153-1161. Date of Electronic Publication: 2018 Jul 19.